No abstract available.
Humans* ; Insulin* ; Receptor, Insulin*

No abstract available.
Selective Estrogen Receptor Modulators*

Childhood obesity is a global epidemic, which leads to the increasing number of studies on genetic locations associated with obesity-related traits. Polymorphisms of insulin (INS) gene have been shown to be associated with obesity-related phenotypes in Europeans; while insulin receptor (INSR) gene has been associated with energy regulation. Therefore, this study was conducted to investigate the association between the INS (rs689) and INSR (rs3745551) gene polymorphisms with childhood obesity risk in a Malay childhood population. Normal weight (538) and overweight or obese (557) children aged 6-12 years old were genotyped using semi-automated Sequenom iPLEX® Gold. Body mass index (BMI) was calculated from measured body weight and height. The rs689 (T/T: 0.006, A/T: 0.159 and A/A: 0.835) and rs3745551 (G/G: 0.054, A/G: 0.378 and A/A: 0.568) genotype distributions were consistent with Hardy Weinberg equilibrium. The T-minor allele frequency for rs689 was 8.6% and G-minor allele frequency for rs3745551 was 24.3%. Minor allele of INS gene polymorphisms significantly increased risk of obesity among Malay children (sex- and age-adjusted OR=1.580; 95%CI: 1.134-2.201). However, INSR gene polymorphisms were not significantly associated with childhood obesity. In conclusion, the polymorphisms of INS gene, rather than INSR gene, were associated with childhood obesity in the Malay population.
Pediatric Obesity ; Receptor, Insulin

Endocannabinoids and cannabinoid receptors are expressed in various central pain modulation regions. They maintain in dynamic changes in the expression level and distribution under different pathological and physiological conditions. These changes possess advantage as well as disadvantage. Exogenous administration of endocannabinoids exerts analgesic effect in different pain models, which is mainly mediated by the cannabinoid CB1 and CB2 receptors. Inhibition of enzymes for degrading endocannabinoids in different pain models also shows analgesic effect due to the increased local levels of endocannabinoids.
Endocannabinoids ; Humans ; Neuralgia ; Receptor, Cannabinoid, CB1 ; Receptor, Cannabinoid, CB2

No abstract available.
Animals ; Rats* ; Sensory Receptor Cells*

No abstract available.
Interleukin 1 Receptor Antagonist Protein*

Animals ; Humans ; Ligands ; Polymorphism, Genetic ; Receptor Cross-Talk ; physiology ; Receptor, Angiotensin, Type 1 ; physiology ; Receptor, Angiotensin, Type 2 ; genetics ; physiology

No abstract available.
Breast Neoplasms* ; Breast* ; Humans* ; Receptor, erbB-2*

No abstract available.
Korea* ; Myocardial Infarction* ; Purinergic P2Y Receptor Antagonists*

Background: Epidermal Growth Factor Receptor (EGFR) is a transmembrane cell-surface glycoprotein with intrinsic tyrosine kinase activity. EGFR has been shown to stimulate cell proliferation and to enhance the migration and invasiveness of breast cancer. EGFR is expressed in epidermal cell lines and have been implicated in the pathogenesis of many different types of cancer. Objective: To evaluate the level of EGFR transcript in breast cancer and normal tissues; comparison the EGFR transcript level at different development stages and cancer cell types. Subject and methods: Total RNA from 62 tissue samples including 47 breast cancer and 15 normal tissues were extracted; cDNA synthesis by reverse transcript polymerase chain reaction, EGFR transcript level were determined using semi-quantitative RT-PCR. Result and conclusions: EGFR transcript level was highly expressed in breast cancer tissues compared to the normal tissues. Especially, its expression was related to the different status and cancer cell types of breast cancer. There was a difference of EGFR transcript level between histological pathology\u2019s forms of breast cancer in the same stage.
breast cancer ; Epidermal growth factor receptor